News

Factoring in the complex nature of the disease, a group of experts provided perspectives on how clinically meaningful benefit should be viewed, stressing the importance of early intervention.

Results from a recent study suggest that greater cumulative exposure to estrogen throughout a woman’s lifespan could increase her risk of stroke.

ABATE is an ongoing phase 1b/2 trial that assesses the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-24.060 in individuals with prodromal Alzheimer disease with confirmed amyloid pathology on PET.

The pediatric neurologist at Nationwide Children's Hospital discussed the epilepsy research studies that he is excited about in 2023. [WATCH TIME: 4 minutes]

In PHOENIX, 664 participants with ALS will be randomly assigned 3:2 to either AMX0035 or placebo for 48-weeks, followed by an optional open-label extension that will continue to assess for efficacy and safety.

The chief training and education officer at the Parkinson’s Foundation detailed the challenges in disseminating educational materials to the clinical community that could have impacts on Parkinson disease care. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Descartes-08, an investigational autologous RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) has been dosed with the first participant in phase 2b randomized controlled trial.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

A single dose of ubrogepant at its highest FDA-approved strength of 60 mg once daily had no statistically significant effect on atogepant pharmacokinetics.

Neurology News Network for the week ending February 4, 2023. [WATCH TIME: 4 minutes]

The clinical psychologist from Ayer Neuroscience Institute at Hartford Healthcare Headache Center shared some highlights from her recently published survey study on migraine treatment during pregnancy.

The list of women's contributions to the field of medicine is a long one, encompassing the hard work of hundreds of individuals. To highlight some of these pioneers, NeurologyLive® has compiled a timeline of 10 of the moments that matter in the history of women in medicine.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 3, 2023.

The chief training and education officer at the Parkinson’s Foundation discussed the importance of educating healthcare professionals on different specialists that play a role in Parkinson disease management. [WATCH TIME: 2 minutes]

In celebration of Women’s Physician Day, held February 3, 2022, take a look back at some of the latest conversations and news that were driven and delivered by women in neurology.

The director of the Montefiore Einstein Center for the Aging Brain provided insight on expanding the use of the 5-Cog tool, and whether it can be used for other conditions like HIV or COVID-19. [WATCH TIME: 3 minutes]

Treatment with deep brain stimulation resulted in improvements in mean motor scores, reductions levodopa equivalent dosage, and a decrease in neuropsychiatric features.

Majority of women’s healthcare providers reported in a survey feeling either somewhat or very comfortable with recommending or continuing acute treatments for pregnant patients with migraine.

Recruitment has begun for REGENXBIO's AFFINITY BEYOND clinical trial assessing the prevalence of AAV8 antibodies in male patients with Duchenne muscular dystrophy.

The pediatric neurologist at Nationwide Children's Hospital talked about current gaps and potential treatment approvals in epilepsy care for 2023. [WATCH TIME: 4 minutes]

An exergaming program that spanned 8 weeks showed positive effects for patients with multiple sclerosis both with and without restless legs syndrome.

The chief training and education officer at the Parkinson’s Foundation provided perspective on the vast types of medical professionals who can learn from the organization’s new education series. [WATCH TIME: 4 minutes]

With a PDUFA date of October 26, 2023, the FDA will review data from the phase 2b VISION-DMD study, in which vamorolone met its primary end point in change in TTSTAND velocity.

Branaplam, an mRNA splicing modifier, joins the many unsuccessful agents for Huntington disease as biopharma continues to be challenged with trial holds and failures.

Take a look at 5 of the most-anticipated clinical trial data readouts expected in 2023 that neurology health care professionals should keep their eyes on.

Donald Whiting, MD, chair of Allegheny Health Network’s Neurosciences Institute, provided insight on ADvance II, a multinational trial exploring the use of deep brain stimulation in patients with mild Alzheimer disease.

The psychologist and professor in the department of rehabilitation medicine at the University of Washington shared her perspective on the state of mental health care in multiple sclerosis. [WATCH TIME: 4 minutes]